Standardized anthocyanin-rich extract ( DrugBank: - )
1 disease
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 97 | Ulcerative colitis | 1 |
97. Ulcerative colitis
Clinical trials : 2,527 / Drugs : 1,465 - (DrugBank : 259) / Drug target genes : 144 - Drug target pathways : 202
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT04000139 (ClinicalTrials.gov) | April 1, 2019 | 24/6/2019 | Anthocyanin Rich Extract (ACRE) in Patients With Ulcerative Colitis | A Multi-center, Multi-national, Randomized, Double-blind, Placebo Controlled, Parallel Group, Phase IIa Study to Evaluate the Efficacy, Safety and Tolerability of an Anthocyanin-rich Extract (ACRE) in Patients With Ulcerative Colitis | Ulcerative Colitis | Drug: Standardized anthocyanin-rich extract;Drug: Placebo | University of Zurich | Swiss National Science Foundation;The Broad Foundation | Completed | 18 Years | N/A | All | 48 | Phase 2 | Switzerland |